Background
Materials and methods
Patient selection and histologic evaluation
Tissue microarray
Immunohistochemistry
Parameters | Total n = 545 (%) | PTC n = 338 (%) | FC n = 111 (%) | MC n = 69 (%) | PDC n = 23 (%) | AC n = 4 (%) | p-value |
---|---|---|---|---|---|---|---|
ATX | < 0.001 | ||||||
Negative | 368 (67.5) | 220 (65.1) | 102 (91.9) | 22 (31.9) | 21 (91.3) | 3 (75.0) | |
Positive | 177 (32.5) | 118 (34.9) | 9 (8.1) | 47 (68.1) | 2 (8.7) | 1 (25.0) | |
LPA1 | < 0.001 | ||||||
Negative | 292 (53.6) | 169 (50.0) | 73 (65.8) | 44 (63.8) | 5 (21.7) | 1 (25.0) | |
Positive | 253 (46.4) | 169 (50.0) | 38 (34.2) | 25 (36.2) | 18 (78.3) | 3 (75.0) | |
LPA1 (S) | 0.051 | ||||||
Negative | 530 (97.2) | 323 (95.6) | 111 (100.0) | 69 (100.0) | 23 (100.0) | 4 (100.0) | |
Positive | 15 (2.8) | 15 (4.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
LPA2 | < 0.001 | ||||||
Negative | 365 (67.0) | 191 (56.5) | 85 (76.6) | 69 (100.0) | 16 (69.6) | 4 (100.0) | |
Positive | 180 (33.0) | 147 (43.5) | 26 (23.4) | 0 (0.0) | 7 (30.4) | 0 (0.0) | |
LPA3 | < 0.001 | ||||||
Negative | 189 (34.7) | 56 (16.6) | 52 (46.8) | 67 (97.1) | 10 (43.5) | 4 (100.0) | |
Positive | 356 (65.3) | 282 (83.4) | 59 (53.2) | 2 (2.9) | 13 (56.5) | 0 (0.0) |
Interpretation of immunohistochemical staining
Statistical analysis
Results
Basal characteristics of thyroid cancer
Expression of proteins related to the ATX–LPA axis in thyroid cancer
Parameters | Total n = 338 (%) | Histologic subtype | p-value | BRAF V600E mutation status | p-value | ||
---|---|---|---|---|---|---|---|
Follicular variant n = 36 (%) | Conventional type n = 302 (%) | No mutation n = 102 (%) | Mutation n = 238 (%) | ||||
ATX |
0.002
| < 0.001 | |||||
Negative | 220 (65.1) | 32 (88.9) | 188 (62.3) | 91 (89.2) | 129 (54.7) | ||
Positive | 118 (34.8) | 4 (11.1) | 114 (37.7) | 11 (10.8) | 107 (45.3) | ||
LPA1 |
0.014
| < 0.001 | |||||
Negative | 169 (50.0) | 25 (69.4) | 144 (47.7) | 88 (86.3) | 81 (34.3) | ||
Positive | 169 (50.0) | 11 (30.6) | 158 (52.3) | 14 (13.7) | 155 (65.7) | ||
LPA1 (S) | 0.609 | 0.380 | |||||
Negative | 323 (95.6) | 35 (97.2) | 288 (95.4) | 99 (97.1) | 224 (94.9) | ||
Positive | 15 (4.4) | 1 (2.8) | 14 (4.6) | 3 (2.9) | 12 (5.1) | ||
LPA2 |
0.001
| < 0.001 | |||||
Negative | 191 (56.5) | 30 (83.3) | 161 (53.3) | 86 (84.3) | 105 (44.5) | ||
Positive | 147 (43.5) | 6 (16.7) | 141 (46.7) | 16 (15.7) | 131 (55.5) | ||
LPA3 | 0.150 | < 0.001 | |||||
Negative | 56 (16.6) | 9 (25.0) | 47 (15.6) | 42 (41.2) | 14 (5.9) | ||
Positive | 282 (83.4) | 27 (75.0) | 255 (84.4) | 60 (58.8) | 222 (94.1) |
Parameters | Total n = 111 (%) | Minimally invasive type n = 61 (%) | Encapsulated angioinvasive type n = 37 (%) | Widely invasive type n = 13 (%) | p-value |
---|---|---|---|---|---|
ATX | 0.296 | ||||
Negative | 102 (91.9) | 54 (88.5) | 35 (94.6) | 13 (100.0) | |
Positive | 9 (8.1) | 7 (11.5) | 2 (5.4) | 0 (0.0) | |
LPA1 |
0.004
| ||||
Negative | 73 (65.8) | 32 (52.5) | 31 (83.8) | 10 (76.9) | |
Positive | 38 (34.2) | 29 (47.5) | 6 (16.2) | 3 (23.1) | |
LPA2 | 0.987 | ||||
Negative | 85 (76.6) | 47 (77.0) | 28 (75.7) | 10 (76.9) | |
Positive | 26 (23.4) | 14 (23.0) | 9 (24.3) | 3 (23.1) | |
LPA3 | 0.792 | ||||
Negative | 52 (46.8) | 27 (44.3) | 19 (51.4) | 6 (46.2) | |
Positive | 59 (53.2) | 34 (55.7) | 18 (48.6) | 7 (53.8) |
Parameters | ATX | LPA1 | LPA1 (S) | LPA2 |
---|---|---|---|---|
LPA1 | ||||
Correlation coefficient | 0.434 | |||
p-value | < 0.001 | |||
LPA1 (S) | ||||
Correlation coefficient | 0.053 | 0.187 | ||
p-value | 0.330 |
0.001
| ||
LPA2 | ||||
Correlation coefficient | 0.459 | 0.591 | 0.188 | |
p-value | < 0.001 | < 0.001 |
0.001
| |
LPA3 | ||||
Correlation coefficient | 0.193 | 0.318 | 0.019 | 0.295 |
p-value | < 0.001 | < 0.001 | 0.731 | < 0.001 |
Correlations between clinicopathologic factors and expression of proteins related to the ATX–LPA axis in thyroid cancer
Impact of the expression of proteins related to the ATX–LPA axis on prognosis of thyroid cancer
Parameter | Number of patients/recurrence/death | Disease-free survival | Overall survival | ||
---|---|---|---|---|---|
Mean survival (95% CI) months | p-value | Mean survival (95% CI) months | p-value | ||
ATX | 0.894 |
0.050
| |||
Negative | 220/12/8 | 106 (103–109) | 109 (107–111) | ||
Positive | 118/6/10 | 104 (101–108) | 102 (98–106) | ||
LPA1 | 0.670 |
0.014
| |||
Negative | 169/10/4 | 106 (103–109) | 110 (109–112) | ||
Positive | 169/8/14 | 107 (104–110) | 105 (101–108) | ||
LPA1 (S) | 0.156 | 0.909 | |||
Negative | 323/16/17 | 107 (105–109) | 108 (106–109) | ||
Positive | 15/2/1 | 96 (79–113) | 102 (89–116) | ||
LPA2 | 0.947 | 0.316 | |||
Negative | 191/10/8 | 107 (104–110) | 108 (106–111) | ||
Positive | 147/8/10 | 106 (103–110) | 106 (103–110) | ||
LPA3 | 0.209 | 0.204 | |||
Negative | 56/1/1 | 108 (104–111) | 108 (106–111) | ||
Positive | 282/17/17 | 106 (103–109) | 107 (105–109) |
Included parameters | Disease-free survival | Overall survival | ||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | p-value | Hazard ratio | 95% CI | p-value | |
Age (years) | 0.617 |
0.007
| ||||
< 45 versus ≥ 45 | 1.282 | 0.485–3.389 | 16.39 | 2.129–126.2 | ||
Sex | 0.508 | 0.925 | ||||
Male versus female | 0.700 | 0.244–2.011 | 1.065 | 0.290–3.915 | ||
Tumor size (cm) | 0.816 | 0.188 | ||||
≤ 2.0 versus > 2.0 | 1.134 | 1.134–3.268 | 2.005 | 0.711–5.653 | ||
Tumor extension | 0.378 | 0.440 | ||||
Intrathyroidal versus extrathyroidal | 0.641 | 0.239–1.722 | 0.647 | 0.214–1.955 | ||
LN metastasis |
0.019
| 0.064 | ||||
No versus yes | 5.978 | 1.339–26.69 | 2.940 | 0.939–9.202 | ||
ATX | 0.997 | 0.360 | ||||
Negative versus positive | 0.998 | 0.334–2.981 | 1.633 | 0.571–4.665 | ||
LPA1 | 0.688 | 0.252 | ||||
Negative versus positive | 0.805 | 0.278–2.327 | 2.093 | 0.592–7.403 |